JP6012775B2 - ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物 - Google Patents

ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物 Download PDF

Info

Publication number
JP6012775B2
JP6012775B2 JP2015002271A JP2015002271A JP6012775B2 JP 6012775 B2 JP6012775 B2 JP 6012775B2 JP 2015002271 A JP2015002271 A JP 2015002271A JP 2015002271 A JP2015002271 A JP 2015002271A JP 6012775 B2 JP6012775 B2 JP 6012775B2
Authority
JP
Japan
Prior art keywords
pyridin
salt
castor oil
pharmaceutical composition
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015002271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015147762A5 (https=
JP2015147762A (ja
Inventor
洋子 遠藤
洋子 遠藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to JP2015002271A priority Critical patent/JP6012775B2/ja
Publication of JP2015147762A publication Critical patent/JP2015147762A/ja
Publication of JP2015147762A5 publication Critical patent/JP2015147762A5/ja
Application granted granted Critical
Publication of JP6012775B2 publication Critical patent/JP6012775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015002271A 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物 Active JP6012775B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015002271A JP6012775B2 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10
JP2014002809 2014-01-10
JP2015002271A JP6012775B2 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016181739A Division JP6449205B2 (ja) 2014-01-10 2016-09-16 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Publications (3)

Publication Number Publication Date
JP2015147762A JP2015147762A (ja) 2015-08-20
JP2015147762A5 JP2015147762A5 (https=) 2016-09-23
JP6012775B2 true JP6012775B2 (ja) 2016-10-25

Family

ID=53523959

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015002271A Active JP6012775B2 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2016181739A Active JP6449205B2 (ja) 2014-01-10 2016-09-16 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2018227964A Active JP6793172B2 (ja) 2014-01-10 2018-12-05 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2020186245A Active JP7170020B2 (ja) 2014-01-10 2020-11-09 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2022174719A Active JP7546027B2 (ja) 2014-01-10 2022-10-31 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016181739A Active JP6449205B2 (ja) 2014-01-10 2016-09-16 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2018227964A Active JP6793172B2 (ja) 2014-01-10 2018-12-05 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2020186245A Active JP7170020B2 (ja) 2014-01-10 2020-11-09 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2022174719A Active JP7546027B2 (ja) 2014-01-10 2022-10-31 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Country Status (19)

Country Link
US (3) US20160317512A1 (https=)
EP (2) EP3093021B1 (https=)
JP (5) JP6012775B2 (https=)
KR (6) KR102111157B1 (https=)
CN (2) CN105828817B (https=)
AU (1) AU2015205268B2 (https=)
BR (1) BR112016015911B1 (https=)
CA (1) CA2934612C (https=)
EA (1) EA031723B1 (https=)
ES (2) ES2953346T3 (https=)
GE (2) GEAP201814216A (https=)
IL (1) IL246654B (https=)
MX (1) MX2016009058A (https=)
MY (1) MY166210A (https=)
PH (1) PH12016501327A1 (https=)
SG (1) SG11201605532YA (https=)
TW (1) TWI612960B (https=)
UA (1) UA121744C2 (https=)
WO (1) WO2015105134A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017031177A (ja) * 2014-01-10 2017-02-09 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
US10485872B2 (en) 2014-01-10 2019-11-26 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20186917B (en) 2014-01-10 2018-11-12 Pharmaceutical Co Ltd Santen Pharmaceutical preparation including pyridylamino acetic acid compound
EP3320904B1 (en) 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
TWI842679B (zh) 2017-09-29 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥
WO2019124487A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ
CN111526876A (zh) * 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
CN114761022B (zh) * 2019-11-29 2024-02-13 千寿制药株式会社 药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
HUE042839T2 (hu) 2008-03-12 2019-07-29 Ube Industries Piridilaminoecetsav vegyületek
HRP20160104T1 (hr) 2009-03-30 2016-03-25 Ube Industries Farmaceutski pripravak za liječenje ili prevenciju glaukoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
BR112016015909B1 (pt) * 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
ES2953346T3 (es) * 2014-01-10 2023-11-10 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto de ácido piridilaminoacético y aceite de ricino polioxietilenado
GEP20186917B (en) * 2014-01-10 2018-11-12 Pharmaceutical Co Ltd Santen Pharmaceutical preparation including pyridylamino acetic acid compound

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017031177A (ja) * 2014-01-10 2017-02-09 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2019034973A (ja) * 2014-01-10 2019-03-07 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
US10485872B2 (en) 2014-01-10 2019-11-26 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
US10765750B2 (en) 2014-01-10 2020-09-08 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
JP2021011508A (ja) * 2014-01-10 2021-02-04 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP7170020B2 (ja) 2014-01-10 2022-11-11 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2022189964A (ja) * 2014-01-10 2022-12-22 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP7546027B2 (ja) 2014-01-10 2024-09-05 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Also Published As

Publication number Publication date
TWI612960B (zh) 2018-02-01
AU2015205268B2 (en) 2019-03-14
US20160317512A1 (en) 2016-11-03
EP3888654B1 (en) 2023-06-14
MX2016009058A (es) 2016-09-09
EP3093021A1 (en) 2016-11-16
KR20160100977A (ko) 2016-08-24
PH12016501327B1 (en) 2017-02-06
JP6793172B2 (ja) 2020-12-02
SG11201605532YA (en) 2016-08-30
JP7170020B2 (ja) 2022-11-11
KR20240096869A (ko) 2024-06-26
CN110251516B (zh) 2022-05-03
KR20220146691A (ko) 2022-11-01
HK1224191A1 (zh) 2017-08-18
JP7546027B2 (ja) 2024-09-05
UA121744C2 (uk) 2020-07-27
IL246654B (en) 2020-05-31
GEAP201814216A (en) 2018-07-25
CA2934612A1 (en) 2015-07-16
KR102111157B1 (ko) 2020-05-14
MY166210A (en) 2018-06-22
JP6449205B2 (ja) 2019-01-09
CN105828817A (zh) 2016-08-03
ES2874547T3 (es) 2021-11-05
EA201691139A1 (ru) 2017-02-28
WO2015105134A1 (ja) 2015-07-16
KR102458180B1 (ko) 2022-10-21
EP3888654A1 (en) 2021-10-06
CA2934612C (en) 2021-09-07
JP2021011508A (ja) 2021-02-04
US20200113880A1 (en) 2020-04-16
NZ721530A (en) 2021-03-26
CN105828817B (zh) 2019-07-05
US20230372316A1 (en) 2023-11-23
EA031723B1 (ru) 2019-02-28
KR102230683B1 (ko) 2021-03-19
EP3093021B1 (en) 2021-06-02
KR20180050770A (ko) 2018-05-15
KR20210032547A (ko) 2021-03-24
KR102675685B1 (ko) 2024-06-14
JP2019034973A (ja) 2019-03-07
JP2015147762A (ja) 2015-08-20
IL246654A0 (en) 2016-08-31
EP3093021A4 (en) 2017-07-26
GEP20186916B (en) 2018-11-12
ES2953346T3 (es) 2023-11-10
KR20200053651A (ko) 2020-05-18
AU2015205268A1 (en) 2016-07-14
BR112016015911A2 (https=) 2017-08-08
JP2022189964A (ja) 2022-12-22
TW201611833A (en) 2016-04-01
BR112016015911B1 (pt) 2022-04-05
PH12016501327A1 (en) 2017-02-06
KR101858373B1 (ko) 2018-05-15
CN110251516A (zh) 2019-09-20
JP2017031177A (ja) 2017-02-09

Similar Documents

Publication Publication Date Title
JP7170020B2 (ja) ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP6441087B2 (ja) ピリジルアミノ酢酸化合物含有医薬組成物
CN105899209B (zh) 含有吡啶基氨基乙酸化合物的药物制剂
HK1224191B (zh) 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物
HK1227322A1 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
NZ721530B2 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
HK1227322B (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160808

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160808

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160920

R150 Certificate of patent or registration of utility model

Ref document number: 6012775

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250